Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MSP-1014

From Wikipedia, the free encyclopedia
Psychedelic drug

Pharmaceutical compound
MSP-1014
Clinical data
Other namesMSP1014; MSP-1014.OX
Routes of
administration
Oral[1][2]
Drug classSerotonin receptoragonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen

MSP-1014 is aserotonergic psychedelic which is under development for the treatment ofmajor depressive disorder, otherdepressive disorders, andanxiety disorders.[3][4][5][1][2]

It is aprodrug ofpsilocin similarly topsilocybin, and hence acts as anon-selectiveserotonin receptoragonist, including of the serotonin5-HT2A receptor.[3][5][2][6]

The drug is under development by Mindset Pharma andOtsuka America Pharmaceutical.[3][4][5] As of January 2024, it is inphase 2clinical trials for major depressive disorder and is in thepreclinical stage of development for anxiety disorders and other depressive disorders.[3][4][5] Thechemical structure of MSP-1014 does not yet seem to have been disclosed.[3][4] However, Mindset Pharmapatented psilocinderivatives and prodrugs in 2022.[7]

See also

[edit]

References

[edit]
  1. ^abMindset Pharma (14 November 2022)."Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate".GlobeNewswire News Room (Press release). Retrieved29 October 2024.
  2. ^abcAraujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022.https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
  3. ^abcde"MSP 1014".AdisInsight. 9 January 2024. Retrieved29 October 2024.
  4. ^abcd"Delving into the Latest Updates on MSP-1014 with Synapse".Synapse. 26 October 2024. Retrieved29 October 2024.
  5. ^abcd"Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder".BioSpace. 22 June 2023. Retrieved29 October 2024.MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin.
  6. ^Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, et al. (July 2022)."Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy".CNS Spectrums.28 (4):416–426.doi:10.1017/S1092852922000888.PMID 35811423.
  7. ^US 2022/0289774, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders", issued 7 March 2023, assigned to Mindset Pharma Inc. 
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Stub icon

Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MSP-1014&oldid=1320377645"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp